Compare Schlumberger NV (SLB) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schlumberger NV vs Summit Therapeutics Inc — how do they compare? Schlumberger NV trades at $48.87 (market cap $72.69B), while Summit Therapeutics Inc trades at $17.38 (market cap $13.71B). The key difference: Schlumberger NV is far larger — about 5.3× Summit Therapeutics Inc's market cap, and Schlumberger NV pays a 2.41% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Schlumberger NV for 99 Days and Summit Therapeutics Inc for 16 Days on average.
| SLB | SMMT | |
|---|---|---|
Market Cap | $72.69B | $13.71B |
Volume | 16,228,451 | 6,173,057 |
Sector | Energy | Health |
52-Week High | $60.10 | $26.38 |
52-Week Low | $31.72 | $12.43 |
Typical Hold Time | 99 Days | 16 Days |
Enterprise Value | $81.42B | $13.04B |
Dividend Yield | 2.41% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLB trades at $48.91, up 1.98% today, with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 8.53% net margin and 13.37% ROE, supported by recent contract wins in Saudi Arabia and Mozambique. Revenue declined slightly to $35.71B in 2025, but operating cash flow remains robust at $6.49B. Analyst consensus is strongly bullish with 85% buy ratings and $64.58 price target, representing 32% upside potential.
SLB presents a compelling value opportunity with strong fundamentals and positive analyst sentiment, though technical indicators suggest near-term weakness. The stock's current valuation at 23.89 P/E appears reasonable given the company's contract momentum and global energy technology leadership. Key risks include energy price volatility and execution challenges in new projects, but the dividend yield and institutional support provide downside protection.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
